Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma

British Journal of Cancer

Volumn 97, Issue 1, 2007, Pages 37-42

  Yamanaka, T ^a   Matsumoto, S ^b   Teramukai, S ^b,c   Ishiwata, R ^c   Nagai, Y ^c   Fukushima, M ^b,c  

^a NATIONAL KYUSHU CANCER CENTER   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c Translational Research Informatics Center   (Japan)

Author keywords

Gastric cancer; Neutropenia; Prognosis; S 1; Time dependent variable

Indexed keywords

FLUOROPYRIMIDINE; TX 1; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ADVERSE OUTCOME; AGED; ARTICLE; BONE MARROW; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NEUTROPENIA; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HAZARD RATIO; HEALTH SURVEY; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; NEUTROPENIA; OUTCOME ASSESSMENT; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; STATISTICAL ANALYSIS; STOMACH CARCINOMA; SURVIVAL RATE; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; OXONIC ACID; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TEGAFUR;

EID: 34347334619     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603831     Document Type: Article

References (26)

1. Balkwill F (2004) Cancer and the chemokine network. Nat Rev Cancer 4: 540-550
2. Cameron DA, Massie C, Kerr G, Leonard RC (2003) Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer. Br J Cancer 89: 1837-1842
3. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420: 860-867
4. Crawford J, Dale DC, Lyman GH (2004) Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 100: 228-237
5. Di Maio M, Gridelli C, Gallo C, Shepherd F, Piantedosi FV, Cigolari S, Manzione L, Illiano A, Barbera S, Robbiati SF, Frontini L, Piazza E, Ianniello GP, Veltri E, Castiglione F, Rosetti F, Gebbia V, Seymour L, Chiodini P, Perrone F (2005) Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol 6: 669-677
6. Fisher B, Anderson S, Wickerham DL, DeCillis A, Dimitrov N, Mamounas E, Wolmark N, Pugh R, Atkins JN, Meyers FJ, Abramson N, Wolter J, Bornstein RS, Levy L, Romond EH, Caggiano V, Grimaldi M, Jochimsen P, Deckers P (1997) Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 15: 1858-1869
7. Frei E, Canellos GP (1980) Dose: a critical factor in cancer chemotherapy. Am J Med 69: 585-594
8. Fumoleau P, Devaux Y, Vo Van ML, Kerbrat P, Fargeot P, Schraub S, Mihura J, Namer M, Mercier M (1993) Premenopausal patients with node-positive resectable breast cancer. Preliminary results of a randomised trial comparing 3 adjuvant regimens: FEC 50 x 6 cycles vs FEC 50 x 3 cycles vs FEC 75 x 3 cycles. The French Adjuvant Study Group. Drugs 45(Suppl 2): 38-45
9. Green S, Benedetti J, Crowley J (2002) Clinical Trials in Oncology. Boca Raton: Chapman & Hall/CRC
10. Gurney H (1996) Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 14: 2590-2611
11. Gurney H (2002) How to calculate the dose of chemotherapy. Br J Cancer 86: 1297-1302
12. Hosmer D, Lemeshow S (1999) Applied Survival Analysis: Regression Modeling of Time to Event Data. New York: John Wiley & Sons
13. Hryniuk W, Levine MN (1986) Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 4: 1162-1170
14. Koizumi W, Kurihara M, Nakano S, Hasegawa K (2000) Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 58: 191-197
15. Kvinnsland S (1999) The leucocyte nadir, a predictor of chemotherapy efficacy? Br J Cancer 80: 1681
16. Mayers C, Panzarella T, Tannock IF (2001) Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer 91: 2246-2257
17. Nakata B, Tsuji A, Mitachi Y, Yamamitsu S, Hirata K, Takeuchi T, Shirasaka T, Hirakawa K (2006) Moderate neutropenia with S-1 plus low-dose cisplatin may predict a more favourable prognosis in advanced gastric cancer. Clin Oncol 18: 678-683
18. Newell DR (2002) Getting the right dose in cancer chemotherapy - time to stop using surface area? Br J Cancer 86: 1207-1208
19. Poikonen P, Saarto T, Lundin J, Joensuu H, Blomqvist C (1999) Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF. Br J Cancer 80: 1763-1766
20. Ratain MJ (1998) Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit? J Clin Oncol 16: 2297-2298
21. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348: 2609-2617
22. Saarto T, Blomqvist C, Rissanen P, Auvinen A, Elomaa I (1997) Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. Br J Cancer 75: 301-305
23. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T (1998) Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur-0.4M gimestat-1M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34: 1715-1720
24. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7: 548-557
25. Simon R, Makuch RW (1984) A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder vs non-responder bias. Stat Med 3: 35-44
26. Wood WC, Budman DR, Korzun AH, Cooper MR, Younger J, Hart RD, Moore A, Ellerton JA, Norton L, Ferree CR, Ballow AC, Frei E, Henderson IC (1994) Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330: 1253-1259